Multicenter randomised trial of chlorambucil versus chlorambucil plux rituximab versus rituximab alone in extranodal marginal zone B-Cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma).
The aim of this study is to assess the therapeutic activity and safety of the combination of Chlorambucil and Rituximab in MALT lymphomas and to determine whether the addition of Rituximab to Chlorambucil will improve the outcome of MALT lymphoma in comparison to treatment with Chlorambucil alone.
In April 2006, a third arm of treatment was added to compare the antitumor activity and safety of rituximab alone vs chlorambucil alone.
This is a multicenter randomized phase III trial.
Completed
450 patients from 8 countries with Extranodal Marginal Zone B-cell lymphoma of Mucosa Associated Lymphoid Tissue.
All Trial enquiries should be addressed to ctu@soton.ac.uk